Virchows Archiv

, Volume 424, Issue 2, pp 187–193 | Cite as

p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos

  • B. G. Schneider
  • V. Pekkel
  • C. H. Shelton
  • D. R. Pulitzer
  • D. C. Allred
  • S. G. Hilsenbeck
  • C. H. Hensel
  • H. A. Rodríguez-Martínez
  • M. E. Gutiérrez-Díaz C.
Original Article
Received:
Accepted:

Abstract

Gastric cancer is more than twice as common in Hispanics as in Anglos in Texas, while colorectal cancer is almost twice as common in Anglos as Hispanics. To test the hypothesis that mutations in the p53 tumour suppressor gene are involved in these differences, we examined 131 gastric and 138 colorectal cancers from Hispanic and Anglo patients from South Texas and Mexico using immunohistochemistry (IHC) as a screening assay for p53 mutations. The fraction of p53 positive cases was not significantly different in gastric cancers from Hispanics compared to Anglos (43% versus 61%, respectively, p=0.13) or in colorectal cancer (57% versus 58%, respectively, p=1.0), suggesting that p53 mutations are not involved in causing the different incidences of these cancers in these populations. In addition, the types of p53 mutations arising in gastric tumours from Hispanic patients were consistent with those reported in gastric tumours in other populations. Sequencing of mutations in five gastric cancers revealed two G: C to A: T transitions, two A: T to G: C transitions and one complex deletion. In contrast with findings in studies in other tumour types, neither stage nor survival was associated with p53 positive staining by IHC in either gastric or colorectal tumours in this study. Positive p53 immunostaining was associated with the diffuse histological subtype in gastric carcinoma (p=0.05) and high histological grade in colorectal carcinoma (p=0.04).

Key words

Adenocarcinoma Immunohistochemistry Tumour suppressor gene Ethnicity 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agarwal RC, Wiessler M, Hecker E, Bhide SV (1986) Tumourpromoting effect of chili extract in Balb/c mice. Int J Cancer 38:689–695Google Scholar
  2. Allred DC, Clark GM, Elledge R, Fuqua S, Brown RW, Chamness GC, Osborne CK, McGuire WL (1993) Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200–206Google Scholar
  3. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JKV, Hamilton S, Vogelstein B (1990) p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717–7722Google Scholar
  4. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ (1992) Manual for staging of cancer. J.B. Lippincott, Philadelphia, chaps 10, 12Google Scholar
  5. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, Taylor GR, Dixon MF, Quirke P (1993) Prognostic value of p53 over-expression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104:57–64Google Scholar
  6. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF, Linnoila RI (1992) Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743–749Google Scholar
  7. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC (1993) p53 is mutated in a subset of advance-stage prostate cancers. Cancer Res 53:3369–3373Google Scholar
  8. Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429–431Google Scholar
  9. Campo E, de la Calle-Martin O, Miguel R, Palacin A, Romero M, Fabregat V, Vives J, Cardisa A, Yague J (1991) Loss of heterogygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res 51:4436–4442Google Scholar
  10. Correa P, Fox J, Fontham E, Ruiz B, Lin Y, Zavala D, Taylor N, Mackinley D, de Lima E, Portillo H, Zarama G (1990) Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer 66:2569–2574Google Scholar
  11. Cunningham J, Lust JA, Schaid DJ, Bren GD, Carpenter HA, Rizza E, Kovach JS, Thibodeau SN (1992) Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 52:1974–1980Google Scholar
  12. Ehrlich M, Wang R Y.-H. (1981) 5-Methylcytosine in eukaryotic DNA. Science 212:1350–1357Google Scholar
  13. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms a hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531–539Google Scholar
  14. Forman D, Silas F, Newell DG, Stacey AR, Boreham J, Peto R, Campbell TC, Li J, Chen J (1990) Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer 46:608–611Google Scholar
  15. Hensel CH, Xiang RH, Sakaguchi AY, Naylor SL (1991) Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer. Oncogene 6:1067–1071Google Scholar
  16. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53PubMedGoogle Scholar
  17. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427–428Google Scholar
  18. Imazeki F, Omata M, Nose H, Ohto M, Isono K (1992) p53 Gene mutations in gastric and esophageal cancers. Gastroenterology 103:892–896Google Scholar
  19. Isola J, Visakorpi T, Holli K, Kallioniemi OP (1992) Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109–1114Google Scholar
  20. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K (1993) Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 67:589–593Google Scholar
  21. Kikuchi-Yanoshita R, Konishi M, Ito S, Seki M, Tanaka K, Maeda Y, Iino H, Fukayama M, Koike M, Mori T, Sakuraba H, Fukunari H, Iwama T, Miyaki M (1992) Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 52:3965–3971Google Scholar
  22. Kim J-H, Takahashi T, Chiba I, Park J-G, Birrer MJ, Roh JK, Lee HD, Kim J-P, Minna JD, Gazdar AF (1991) Occurrence of p53 gene abnormalities in gastric carcinoma tumours and cell lines. J Natl Cancer Inst 83:938–943Google Scholar
  23. Laurén P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64:31–49PubMedGoogle Scholar
  24. Lawson T, Gannett P (1989) The mutagenicity of capsaicin and dihydrocapsaicin in V79 cells. Cancer Lett 48:109–113Google Scholar
  25. Loffeld RJLF, Willems I, Flendrig JA, Arends JW (1990) Helicobacter pylori and gastric carcinoma. Histopathology 17:537–541Google Scholar
  26. Malaty HM, Evans DG, Evans DJ, Graham DY (1992) Helicobacter pylori in Hispanics: comparison with blacks and whites of similar age and socioeconomic class. Gastroenterology 103:813–816Google Scholar
  27. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F (1992) p53 expression and prognosis in gastric carcinoma. Int J Cancer 50:859–862Google Scholar
  28. Matozaki T, Sakamoto C, Suzuki T, Matsuda K, Uchida T, Nakano O, Wada K, Nishisaki H, Konda Y, Nagao M, Kasuga M (1992) p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Cancer Res 52:4335–4341Google Scholar
  29. Mor O, Grossman Z, Jakobovitz O, Brok SF, Rechavi G (1992) Artifactual p53 point mutations: possible effect of gene secondary structure on PCR and direct sequence analysis. Lancet 340:1236–1236Google Scholar
  30. Nagabhushan M, Bhide SV (1985) Mutagenicity of chili extract and capsaicin in short-term tests. Environ Mutagen 7:881–888Google Scholar
  31. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins TS, Weston A, Modali R, Harris C, Vogelstein B (1989) Mutations in the p53 gene occur in diverse tumor types. Nature 342:705–708Google Scholar
  32. Nomura A, Stimmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ (1991) Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325:1132–1136PubMedGoogle Scholar
  33. Oren M (1985) The p53 cellular tumor antigen: gene structure, expression and protein properties. Biochim Biophys Acta 823:67–78Google Scholar
  34. Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874–879PubMedGoogle Scholar
  35. Parkin DM, Läärä E, Muir CS (1988) Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41:184–197Google Scholar
  36. Parsonnet J, Freidman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK (1991a) Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325:1127–1131PubMedGoogle Scholar
  37. Parsonnet J, Vandersteen D, Goates J, Sibley RK, Pritikin J, Chang Y (1991b) Helicobacter infection in intestinal- and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst 83:640–643Google Scholar
  38. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828–4831Google Scholar
  39. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM, Ranzani GN (1993) Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 53:2614–2617Google Scholar
  40. Sarkis AS, Dalbagni G, Cordon CC, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85:53–59PubMedGoogle Scholar
  41. Scott N, Sagar P, Steward J, Blair GE, Dixon MF, Quirke P (1991) p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63:317–319Google Scholar
  42. Seruca R, David L, Holm R, Nesland JM, Fangan BM, Castedo S, Sobrinho-Simões M, Borresen AL (1992) p53 mutations in gastric carcinomas. Br J Cancer 65:708–710Google Scholar
  43. Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V (1990) Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 10:6565–6577Google Scholar
  44. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G (1992) Frequent p53 mutations in head and neck cancer. Cancer Res 52:5997–6000Google Scholar
  45. Starzynska T, Bromley M, Ghosh A, Stern PL (1992) Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66:558–562Google Scholar
  46. Sun XF, Carstensen JM, Zhang H, St»l O, Wingren S, Hatschek T, Nordenskjöld B (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340:1369–1373Google Scholar
  47. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S (1991) Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res 51:3056–3058Google Scholar
  48. Texas Department of Health. Texas Cancer Incidence Data (1976–1985).Google Scholar
  49. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845–855Google Scholar
  50. Toth B, Rogan E, Walker B (1984) Tumorigenicity and mutagenicity studies with capsaicin of hot peppers. Anticancer Res 4:117–120Google Scholar
  51. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883–887Google Scholar
  52. Vojtesek B, Bártek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 151:237–244Google Scholar
  53. Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, Hirohashi S, Nakatani K, Nakano H, Sugimura T, Terada M (1991) p53 Gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 51:5800–5805Google Scholar
  54. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki I (1992) Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70:2778–2784Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • B. G. Schneider
    • 1
  • V. Pekkel
    • 1
  • C. H. Shelton
    • 1
  • D. R. Pulitzer
    • 1
  • D. C. Allred
    • 1
  • S. G. Hilsenbeck
    • 2
  • C. H. Hensel
    • 3
  • H. A. Rodríguez-Martínez
    • 4
  • M. E. Gutiérrez-Díaz C.
    • 4
  1. 1.Department of PathologyUniversity of Texas Health Science Center at San AntonioSan AntonioUSA
  2. 2.Department of MedicineUniversity of Texas Health Science Center at San AntonioSan AntonioUSA
  3. 3.Department of Cellular and Structural BiologyUniversity of Texas Health Science, Center at San AntonioSan AntonioUSA
  4. 4.Hospital General de MéxicoUniversidad Nacional AutónomaMexico CityMexico

Personalised recommendations